*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.
GEN’s editorial staff interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.
Go to any scientific or biotech conference and chances are a good part of the program will be devoted to some aspect of proteomics and biomarker research. Over the past decade these two related research areas have drawn much attention as investigators seek to shed as much light as possible on the role of proteins in health and disease. One of main goals of this work is to get important research findings into the clinic as quickly as possible. Today’s podcast interviewee is one of the scientists at the forefront in carrying out such translational research.
This week's podcast interviewee is one of the scientists at the forefront in carrying out such translational research.The Director of the Fred Hutchinson Cancer Research Center's Early Detection Initiative, Dr. Amanda Paulovich tells us how proteomics can help move new cancer therapies more effectively out of the lab and into clinical applications. She explains what various proteomics approaches allow researchers and cancer clinicians to do now that was impossible ten or fifteen years ago. Dr. Paulovich provides details on which particular instruments and technologies used in proteomics research and clinical proteomic applications are essential to this effort of translating lab discoveries to the cancer clinic. She provides examples of proteomic alterations that may reflect the existence of cellular and molecular pathways linked to tumorigenesis and shows how these proteomic changes are measured in the serum/plasma proteome. She also discusses the best methods for describing and comparing proteomic data representation, and lists the advantages and disadvantages of the different techniques.
listen now to this important discussion then return to the blog to give your thoughts on the following question:
What improvements in which specific tools and technologies do you think are necessary to help accelerate the transfer of research findings in proteomics and biomarkers into clinical applications?
Dr. Amanda Paulovich, M.D. Ph.D. is a medical oncologist and Director of the Early Detection Initiative at the Fred Hutchinson Cancer Research Center. She earned M.D. and Ph.D degrees at the University of Washington. While a graduate student in Genetics, she trained in the laboratory of Nobel laureate Dr. Leland Hartwell studying checkpoint regulation of cell cycle progression in yeast in response to DNA damaging agents as well as genetic mechanisms used by yeast cells to tolerate irreparable DNA damage. She subsequently did a residency in Internal Medicine at Massachusetts General Hospital, a Fellowship in Medical Oncology at the Dana Farber Cancer Institute, and postdoctoral training with Dr. Eric Lander at the Broad Institute of Massachusetts Institute of Technology. In September 2003, Dr. Paulovich joined the faculty of the Clinical Research Division at the Fred Hutchinson Cancer Research Center as Director of the Center’s new Early Detection Initiative, and is continuing to pursue her interest in biomarkers of cancer risk and detection, using proteomic technologies such as mass spectrometry. She participates in several large, multi-institutional biomarker discovery initiatives and is a Steering Committee member for the International Cancer Biomarker Consortium (ICBC), a large-scale effort similar to the Human Genome Project aimed at making significant progress in the discovery of biomarkers by facilitating highly coordinated research and leveraging resources and expertise from around the world. She also serves on the advisory Boards of Bio-Rad Laboratories, the Canary Foundation, and the Women’s Bioethics Project.